Article
EU regulator recommends revoking authorisation for Novartis' sickle cell drug
Rating:
0.0
Views:
48
Likes:
1
Library:
1
The European Medicines Agency (EMA) said on Friday it had recommended revoking marketing authorisation for Novartis' sickle cell disease drug Adakveo.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value